<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[136, 141] proportion of patients requiring transfusions<br>[208, 214] hemoglobin (Hb) increment,<br>[225, 228] high Hb,<br>[231, 242] mean end-of-study Hb levels. Toxicities,<br>[243, 245] thromboembolism,<br>[246, 248] overall survival<br>[259, 266] global quality of life (QOL)<br>[281, 284] global QOL improvement<br>[289, 295] end-of-study QOL<br>[331, 333] Hb increment<br></td>
<td width=33%>
[136, 141] proportion of patients requiring transfusions<br>[208, 214] hemoglobin (Hb) increment,<br>[225, 228] high Hb,<br>[231, 240] mean end-of-study Hb levels.<br>[240, 242] Toxicities,<br>[243, 245] thromboembolism,<br>[246, 248] overall survival<br>[259, 266] global quality of life (QOL)<br>[281, 284] global QOL improvement<br>[289, 295] end-of-study QOL<br>[331, 333] Hb increment<br></td>
<td width=33%>
[136, 141] proportion of patients requiring transfusions<br>[208, 214] hemoglobin (Hb) increment,<br>[225, 228] high Hb,<br>[231, 240] mean end-of-study Hb levels.<br>[240, 248] Toxicities, including thromboembolism, and overall survival<br>[258, 266] higher global quality of life (QOL)<br>[280, 284] greater global QOL improvement<br>[289, 295] end-of-study QOL<br>[331, 333] Hb increment<br></td>
</tr>
